NCT02654899

Single Dose Study of PF-06815345 in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06815345, As Well As Characterize The Pharmacokinetics Of Two Formulations And Effect Of Food On Pharmacokinetics Of One Formulation Of Pf-06815345 Administered To Healthy Adult Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult subjects.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	PF-06815345	PF-06815345 will be administered as a liquid dosage formulation
OTHER	Placebo	Placebo
DRUG	PF-06815345	PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation

Timeline

• Start date: 2015-11-01
• Primary completion: 2016-03-01
• Completion: 2016-03-01
• First posted: 2016-01-13
• Last updated: 2018-09-28

Locations

1 site across 1 country: Belgium